Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure

NCT02859324 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02859324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
September 20, 2016
Completion date
March 27, 2020
Enrollment
21 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular